Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials

被引：0
|
作者：
You, B.
Gan, H. K.
Pond, G. R.
Chen, E. X.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Austin Hosp, Melbourne, Vic 3084, Australia
[3] McMaster Univ, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6031
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Re: Quality of Reporting of Modern Randomized Controlled Trials in Medical Oncology: A Systematic Review Response
    Peron, Julien
    You, Benoit
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (03): : 244 - 245
  • [22] Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials
    Sherry, Alexander D.
    Lin, Timothy A.
    McCaw, Zachary R.
    Beck, Esther J.
    Kouzy, Ramez
    Abi Jaoude, Joseph
    Passy, Adina H.
    Miller, Avital M.
    Kupferman, Gabrielle S.
    Fuller, Clifton David
    Thomas, Charles R.
    Koay, Eugene J.
    Tang, Chad
    Msaouel, Pavlos
    Ludmir, Ethan B.
    INTERNATIONAL JOURNAL OF CANCER, 2024, 155 (11) : 1939 - 1943
  • [23] Treatment group-specific inferences in Phase III Randomized Oncology Trials
    Sherry, Alexander D.
    Passy, Adina H.
    Jaoude, Joseph Abi
    Lin, Timothy A.
    Kouzy, Ramez
    Msaouel, Pavlos
    Ludmir, Ethan B.
    ACTA ONCOLOGICA, 2025, 64 : 470 - 474
  • [24] Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
    Desai, Aakash
    Gyawali, Bishal
    ECLINICALMEDICINE, 2020, 23
  • [25] From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology
    Raghav, Kanwal Pratap Singh
    Mahajan, Sminil
    Yao, James C.
    Hobbs, Brian P.
    Berry, Donald A.
    Pentz, Rebecca D.
    Tam, Alda
    Hong, Waun K.
    Ellis, Lee M.
    Abbruzzese, James
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) : 3583 - +
  • [26] Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials
    Liang, Fei
    Guo, Xinmei
    Zhang, Sheng
    Xue, Hongxi
    Chen, Qiang
    Hu, Xichun
    ONCOTARGET, 2017, 8 (57) : 97648 - 97656
  • [27] Adverse events reporting in phase III oncology clinical trials of checkpoint inhibitors: A systematic review
    Joulia, M-L.
    Barhli, A.
    Tournigand, C.
    Kempf, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S725 - S725
  • [28] An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints
    Jenkins, Martin
    Stone, Andrew
    Jennison, Christopher
    PHARMACEUTICAL STATISTICS, 2011, 10 (04) : 347 - 356
  • [29] Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer
    Barton, Sarah Rachel
    Chau, Ian
    Peckitt, Clare
    Sclafani, Francesco
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [30] Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.
    Rahman, Rifaquat
    Fell, Geoffrey
    Trippa, Lorenzo
    Alexander, Brian Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345